Related Experiment Videos
[Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms]
Abstract:
In spite of the advances attained in the diagnosis and early intervention with antibiotics, morbidity and mortality associated with sepsis caused by Gram-negative bacteria are high. The mediators responsible for the pathogenesis of the sepsis are components derived from the own bacteria (endotoxins) and from the cells of the immune response of the host (tumor necrosis factor and some interleukins). The treatment traditionally used in sepsis is mainly directed against microorganisms by the use of increasingly potent antibiotics. However, it is clear that antibiotics are not a definitive solution, since even when they cause bacterial death, they have no effects on endotoxin and may increase their liberation when cellular lysis occurs. New and successful treatments for sepsis have been tried since the 1980's, including the use of polyclonal and monoclonal antibodies of murine and human origin, directed against the lipid A of the endotoxin, as well as monoclonal antibodies against the tumor necrosis factor. Although these molecules are not completely efficient for the interruption of the chain of undesirable events provoked by the endotoxin, it is valid to accept the appearance of immunotherapies as an adjuvant treatment for a condition that threatens life.
Insights
Sepsis treatment remains challenging despite advances. Immunotherapies targeting endotoxins and tumor necrosis factor offer a promising adjuvant approach to combat Gram-negative bacterial infections.
Area of Science:
- Microbiology
- Immunology
- Pathogenesis
Context:
- Sepsis, particularly from Gram-negative bacteria, presents high morbidity and mortality despite diagnostic and antibiotic advancements.
- Bacterial endotoxins and host immune mediators like tumor necrosis factor (TNF) drive sepsis pathogenesis.
- Current antibiotic treatments are insufficient as they do not neutralize endotoxins and may increase their release.
Purpose:
- To review the limitations of traditional sepsis treatment and explore emerging immunotherapeutic strategies.
- To highlight the role of endotoxins and immune mediators in sepsis progression.
- To evaluate the potential of immunotherapies as adjuvant treatments for sepsis.
Summary:
- Sepsis caused by Gram-negative bacteria remains a significant threat due to high mortality rates.
- While antibiotics target bacteria, they are ineffective against endotoxins and can exacerbate their release.
- Immunotherapies, including antibodies against endotoxin's lipid A and TNF, have been developed as potential adjuvant treatments.
Impact:
- Immunotherapies represent a novel therapeutic avenue for sepsis management.
- These treatments aim to mitigate the damaging effects of endotoxins and inflammatory responses.
- While not a complete solution, immunotherapies offer hope for improving outcomes in life-threatening sepsis cases.